Literature DB >> 28901017

Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Lu Tian1, Haoda Fu2, Stephen J Ruberg2, Hajime Uno3, Lee-Jen Wei4.   

Abstract

In comparing two treatments with the event time observations, the hazard ratio (HR) estimate is routinely used to quantify the treatment difference. However, this model dependent estimate may be difficult to interpret clinically especially when the proportional hazards (PH) assumption is violated. An alternative estimation procedure for treatment efficacy based on the restricted means survival time or t-year mean survival time (t-MST) has been discussed extensively in the statistical and clinical literature. On the other hand, a statistical test via the HR or its asymptotically equivalent counterpart, the logrank test, is asymptotically distribution-free. In this article, we assess the relative efficiency of the hazard ratio and t-MST tests with respect to the statistical power under various PH and non-PH models theoretically and empirically. When the PH assumption is valid, the t-MST test performs almost as well as the HR test. For non-PH models, the t-MST test can substantially outperform its HR counterpart. On the other hand, the HR test can be powerful when the true difference of two survival functions is quite large at end but not the beginning of the study. Unfortunately, for this case, the HR estimate may not have a simple clinical interpretation for the treatment effect due to the violation of the PH assumption.
© 2017, The International Biometric Society.

Entities:  

Keywords:  Asymptotic relative efficiency; Hazard ratio; Proportional hazards model; Survival analysis; t-year mean survival time

Mesh:

Year:  2017        PMID: 28901017      PMCID: PMC5847424          DOI: 10.1111/biom.12770

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  13 in total

1.  The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis.

Authors:  L J Wei
Journal:  Stat Med       Date:  1992 Oct-Nov       Impact factor: 2.373

2.  An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials.

Authors:  Valérie Garès; Sandrine Andrieu; Jean-François Dupuy; Nicolas Savy
Journal:  Stat Med       Date:  2014-11-12       Impact factor: 2.373

3.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

4.  Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.

Authors:  M S Pepe; T R Fleming
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

5.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint.

Authors:  D A Schoenfeld; J R Richter
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

6.  A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.

Authors:  Hajime Uno; Lu Tian; Brian Claggett; L J Wei
Journal:  Stat Med       Date:  2015-07-20       Impact factor: 2.373

7.  Improved logrank-type tests for survival data using adaptive weights.

Authors:  Song Yang; Ross Prentice
Journal:  Biometrics       Date:  2009-04-13       Impact factor: 2.571

8.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

Review 9.  Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.

Authors:  Ludovic Trinquart; Justine Jacot; Sarah C Conner; Raphaël Porcher
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

10.  Power and sample size calculation for log-rank test with a time lag in treatment effect.

Authors:  Daowen Zhang; Hui Quan
Journal:  Stat Med       Date:  2009-02-28       Impact factor: 2.373

View more
  19 in total

1.  How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

Authors:  Miki Horiguchi; Michael J Hassett; Hajime Uno
Journal:  Oncologist       Date:  2018-09-10

2.  An Alternative Approach for the Analysis of Time-to-Event and Survival Outcomes in Pulmonary Medicine.

Authors:  Michael O Harhay; Raphaël Porcher; Edward Cantu; Michael J Crowther; Jason D Christie; Gabriel Thabut; Gavin C Donaldson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

3.  Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies.

Authors:  Zachary R McCaw; Lu Tian; Jiawei Wei; Brian Lee Claggett; Frank Bretz; Garrett Fitzmaurice; Lee-Jen Wei
Journal:  Stat Med       Date:  2021-12-10       Impact factor: 2.373

4.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

5.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

6.  Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.

Authors:  Laila Staerk; Sarah R Preis; Honghuang Lin; Juan P Casas; Kathryn Lunetta; Lu-Chen Weng; Christopher D Anderson; Patrick T Ellinor; Steven A Lubitz; Emelia J Benjamin; Ludovic Trinquart
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-03-31

7.  On the empirical choice of the time window for restricted mean survival time.

Authors:  Lu Tian; Hua Jin; Hajime Uno; Ying Lu; Bo Huang; Keaven M Anderson; L J Wei
Journal:  Biometrics       Date:  2020-02-26       Impact factor: 2.571

8.  Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment Trials.

Authors:  Isabelle R Weir; Sean Wasserman
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

9.  Restricted mean survival time as a function of restriction time.

Authors:  Yingchao Zhong; Douglas E Schaubel
Journal:  Biometrics       Date:  2020-12-17       Impact factor: 2.571

10.  Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials.

Authors:  Ying Lu; Lu Tian
Journal:  Stat Biopharm Res       Date:  2020-10-09       Impact factor: 1.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.